EpiVax Inc, a US-based biotechnology company, has revealed an update on the progress of its peptide therapeutic immunogenicity assessment programme, it was reported on Tuesday.

The programme was initially developed for screening generic peptide drugs and their impurities following the publication of ANDA draft guidance by US Food and Drug Administration. The company performed validation studies of the in silico tools and in vitro validation methods used in the Peptide Abbreviated New Drug Application programme in collaboration with CUBRC.

The company's peptide immunogenicity screening services have increased, now providing around twenty% of its total revenue between 2017 and 2020 in its contracted Peptide Abbreviated New Drug Application peptide immunogenicity research.